Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Harter

Showing results (41-50 of 276) with videos related to

Pageof 28
Sort By:
Gynecologic Oncology|March 17, 2021
Trends in peritoneal cytology evaluation at hysterectomy for endometrial cancer in the United StatesKoji Matsuo, Maximilian Klar, Philipp Harter, et al.
Annals of Surgical Oncology|February 19, 2010
Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group)Pauline Wimberger, Michael Wehling, Nils Lehmann, et al.
Gynecologic Oncology|August 24, 2010
Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinomaStefanie Scheil-Bertram, Patricia Tylus-Schaaf, Andreas du Bois, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 8, 2025
Role of lymphadenectomy in advanced ovarian cancer-a subgroup analysis of the patients excluded from the LION trial (the Charité cohort)Robert Armbrust, Christina Fotopoulou, Dario Zocholl, et al.
Women'S Health (London, England)|September 2, 2011
Surgery for recurrent ovarian cancerFlorian Heitz, Andreas du Bois, Christian Kurzeder, et al.
Geburtshilfe Und Frauenheilkunde|October 27, 2018
Low-grade Serous Ovarian CarcinomaEnzo Ricciardi, Thaïs Baert, Beyhan Ataseven, et al.
Onkologie|February 8, 2012
Borderline tumors of the ovary: clinical course and prognostic factorsNina Ewald-Riegler, Oya du Bois, Annette Fisseler-Eckhoff, et al.
Gynecologic Oncology|July 22, 2020
Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancerKoji Matsuo, David J Nusbaum, Shinya Matsuzaki, et al.
Gynecologic Oncology|April 10, 2014
Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5)Günter Emons, Grigor Gorchev, Jalid Sehouli, et al.
Gynecologic Oncology|April 5, 2012
Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancerJacek P Grabowski, Philipp Harter, Rita Hils, et al.
Pageof 28

Showing results (41-50 of 276) with videos related to

Sort By:
Pageof 28
Gynecologic Oncology|March 17, 2021
Trends in peritoneal cytology evaluation at hysterectomy for endometrial cancer in the United StatesKoji Matsuo, Maximilian Klar, Philipp Harter, et al.
Annals of Surgical Oncology|February 19, 2010
Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group)Pauline Wimberger, Michael Wehling, Nils Lehmann, et al.
Gynecologic Oncology|August 24, 2010
Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinomaStefanie Scheil-Bertram, Patricia Tylus-Schaaf, Andreas du Bois, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 8, 2025
Role of lymphadenectomy in advanced ovarian cancer-a subgroup analysis of the patients excluded from the LION trial (the Charité cohort)Robert Armbrust, Christina Fotopoulou, Dario Zocholl, et al.
Women'S Health (London, England)|September 2, 2011
Surgery for recurrent ovarian cancerFlorian Heitz, Andreas du Bois, Christian Kurzeder, et al.
Geburtshilfe Und Frauenheilkunde|October 27, 2018
Low-grade Serous Ovarian CarcinomaEnzo Ricciardi, Thaïs Baert, Beyhan Ataseven, et al.
Onkologie|February 8, 2012
Borderline tumors of the ovary: clinical course and prognostic factorsNina Ewald-Riegler, Oya du Bois, Annette Fisseler-Eckhoff, et al.
Gynecologic Oncology|July 22, 2020
Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancerKoji Matsuo, David J Nusbaum, Shinya Matsuzaki, et al.
Gynecologic Oncology|April 10, 2014
Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5)Günter Emons, Grigor Gorchev, Jalid Sehouli, et al.
Gynecologic Oncology|April 5, 2012
Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancerJacek P Grabowski, Philipp Harter, Rita Hils, et al.
Pageof 28